Literature DB >> 33352569

SARS-CoV-2 Infection in a Spanish Cohort of CKD-5D Patients: Prevalence, Clinical Presentation, Outcomes, and De-Isolation Results.

José Jesús Broseta1, Diana Rodríguez-Espinosa2, Elena Cuadrado2, Elena Guillén-Olmos2, Evelyn Hermida2, Enrique Montagud-Marrahi2, Lida Rodas2, Manel Vera2, Néstor Fontseré2, Marta Arias2, Aleix Cases2, Francisco Maduell2.   

Abstract

INTRODUCTION: COVID-19 is a highly contagious disease that has easily spread worldwide. Outpatient maintenance hemodialysis seems to entail an increased risk of contagion, and previous reports inform of increased mortality among this population.
METHODS: We retrospectively analyzed clinical and laboratory parameters, outcomes, and management once discharged of CKD-5D patients infected with SARS-CoV-2 from our health area.
RESULTS: Out of the 429 CKD-5D population, 36 were diagnosed with SARS-CoV-2 infection (8%): 34 on in-center hemodialysis and 2 on peritoneal dialysis. Five were asymptomatic. The most common symptom was fever (70%), followed by dyspnea and cough. History of cardiovascular disease and elevation of LDH and C-reactive protein during admission were associated with higher mortality. Thirteen patients died (36%), 8 patients were admitted to an ICU, and survival was low (38%) among the latter. The mean time to death was 12 days. Most discharged patients got negative rRT-PCR in nasopharyngeal swabs within 26 days of diagnosis. However, there is a portion of cured patients that continue to have positive results even more than 2 months after the initial presentation.
CONCLUSIONS: Patients on dialysis have an increased mortality risk if infected with SARS-CoV-2. Preventive measures have proven useful. Thus, proper ones, such as universal screening of the population and isolation when required, need to be generalized. Better de-isolation criteria are necessary to ensure an appropriate use of public health resources.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  COVID-19; De-isolation; Hemodialysis; Peritoneal dialysis; SARS-CoV-2

Mesh:

Year:  2020        PMID: 33352569     DOI: 10.1159/000510557

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  7 in total

Review 1.  Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms.

Authors:  Stefanie Steiger; Jan Rossaint; Alexander Zarbock; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2021-12-14       Impact factor: 10.121

2.  Safety profile and clinical results of Remdesivir in Hemodialysis patients infected with SARS-CoV-2. A single-center Spanish cohort study.

Authors:  Elena Cuadrado-Payán; Diana Rodríguez-Espinosa; José Jesús Broseta; Elena Guillén-Olmos; Francisco Maduell
Journal:  J Nephrol       Date:  2022-06-18       Impact factor: 4.393

Review 3.  The frail world of haemodialysis patients in the COVID-19 pandemic era: a systematic scoping review.

Authors:  Gaetano Alfano; Annachiara Ferrari; Riccardo Magistroni; Francesco Fontana; Gianni Cappelli; Carlo Basile
Journal:  J Nephrol       Date:  2021-08-21       Impact factor: 3.902

4.  Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients.

Authors:  José Jesús Broseta; Diana Rodríguez-Espinosa; Elena Cuadrado; Néstor Rodríguez; José Luis Bedini; Francisco Maduell
Journal:  Vaccines (Basel)       Date:  2022-03-27

5.  Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients.

Authors:  Diana Rodríguez-Espinosa; Enrique Montagud-Marrahi; José Jesús Broseta; David Cucchiari; Judit Cacho; Carolt Arana; Natalia Taurizano; Evelyn Hermida; Jimena Del Risco-Zevallos; Joaquim Casals; Anney Rosario; Elena Cuadrado-Payán; Alicia Molina-Andújar; Néstor Rodríguez; Anna Vilella; Marta Bodro; Pedro Ventura-Aguiar; Ignacio Revuelta; Frederic Cofàn; Esteban Poch; Frederic Oppenheimer; Manel Vera; Lida M Rodas; Aleix Cases; Beatriu Bayés; Fritz Diekmann; Francisco Maduell
Journal:  J Nephrol       Date:  2022-02-21       Impact factor: 4.393

6.  Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients.

Authors:  Diana Rodríguez-Espinosa; José Jesús Broseta; José Luis Bedini; Néstor Rodríguez; Francisco Maduell
Journal:  Clin Kidney J       Date:  2021-12-16

7.  Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.

Authors:  José Jesús Broseta; Diana Rodríguez-Espinosa; Néstor Rodríguez; María Del Mar Mosquera; María Ángeles Marcos; Natalia Egri; Mariona Pascal; Erica Soruco; José Luis Bedini; Beatriu Bayés; Francisco Maduell
Journal:  Am J Kidney Dis       Date:  2021-06-24       Impact factor: 8.860

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.